article thumbnail

Regeneron antibody cuts risk of COVID-19 death in UK study

Bio Pharma Dive

The biotech said it will seek an expanded FDA clearance after results from the RECOVERY trial showed its antibody can lower mortality among certain hospitalized COVID-19 patients

Antibody 261
article thumbnail

Who would get Regeneron's COVID-19 antibody treatment?

Bio Pharma Dive

Fast antibody testing, however, is spotty The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection.

Antibody 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Lilly's COVID-19 antibody cleared by FDA for post-exposure prevention

Bio Pharma Dive

The expanded authorization comes amid surging demand for antibody treatments, particularly in states with lower rates of coronavirus vaccination

Antibody 207
article thumbnail

US FDA approves Eisai-Biogen’s antibody for Alzheimer’s

Pharmaceutical Technology

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD).

article thumbnail

Antibody Drug Conjugates Market: The Future of Novel Therapies

Roots Analysis

Antibody drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have garnered the attention of pharmaceutical companies, and academic / research institutions across the world. Fundamentally, these complex biotherapeutic entities represent the combination of the target specificity of an antibody and the therapeutic features of a chemotherapy / cytotoxic drug. What are the technical challenges related to Antibody Drug Conjugates Market?

article thumbnail

Eli Lilly wins FDA emergency clearance for COVID-19 antibody drug

Bio Pharma Dive

The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact

Antibody 267
article thumbnail

FDA clears Lilly's COVID-19 antibody cocktail for emergency use

Bio Pharma Dive

In a late-stage study of people recently diagnosed with COVID-19, the dual-antibody drug sharply reduced the risk of hospitalizations and death

Antibody 246
article thumbnail

FDA approves Regeneron antibody drug as first Ebola virus treatment

Bio Pharma Dive

Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19

article thumbnail

Versant partners with AbCellera to arm startups with better antibodies

Bio Pharma Dive

The companies pitch their collaboration as a way to give young drugmakers backed by Versant a head start. “Our business is advanced by great ideas coming into the funnel,” said AbCellera’s CEO

Antibody 265
article thumbnail

Scientists identify antibodies that can neutralize omicron

Scienmag

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike protein that remain essentially unchanged as the viruses mutate.

article thumbnail

Bristol Myers partners with Eisai in $650M deal for targeted cancer antibody

Bio Pharma Dive

drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca The U.S.

Antibody 274
article thumbnail

IgY antibody technology against SARS-CoV-2 unveiled

Pharma Mirror

An IgY neutralizing antibody, which is claimed to inhibit the activity of SARS-CoV-2, the novel coronavirus that causes COVID-19, by over 99 percent, was launched in Shenzhen on Monday, according to Shenzhen Special Zone Daily.

Antibody 130
article thumbnail

Antibody discovered by RQ Bio enters pivotal research phase

Pharma Times

AstraZeneca trial will study activity of AZD5156 which includes monoclonal antibody discovered by RQ Bio

Trials 113
article thumbnail

Artificial Intelligence for better antibody drugs: ready for prime time?

Pharma Phorum

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. Naturally, the pharma industry has seen an explosion of mAbs in the pipeline, which has led to the evolution of new methods for improving and refining the antibody pipeline. Natural Antibody.

article thumbnail

UTMB study shows common antibody therapy has anti-SARS-CoV-2 Antibodies

Scienmag

GALVESTON, Texas – Researchers at the University of Texas Medical Branch recently confirmed the presence of neutralizing antibodies to SARS–COV-2 in a common subcutaneous antibody therapy (Hizentra) used to treat immunocompromised or immunodeficient patients, citing its protective benefits to the immunocompromised patient community. Latest News Antibodies antibody antiSARSCoV2 common shows study therapy UTMB

article thumbnail

A startup raises $336M to make a better antibody drug for COVID-19

Bio Pharma Dive

Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests

Antibody 267
article thumbnail

AstraZeneca to deliver Covid-19 antibody therapy doses to Switzerland

Pharmaceutical Technology

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment.

Antibody 219
article thumbnail

Breakthrough COVID-19 infections spur strong antibody responses

Scienmag

A recent study looked at the strength, durability and breadth of neutralizing antibody responses generated by breakthrough infections in individuals vaccinated against SARS-CoV2. Medicine & Health antibody breakthrough COVID19 infections responses spur strong

article thumbnail

US stops rollout of Lilly's first COVID-19 antibody over variant concerns

Bio Pharma Dive

Treatments from Lilly and Regeneron that combine two different antibodies should be used instead, according to health officials

Antibody 239
article thumbnail

J&J's new cancer drug leads a growing pipeline of dual-targeting antibodies

Bio Pharma Dive

Pharma and biotech companies alike see potential in using bispecific antibodies for hard-to-treat cancers like leukemia, myeloma and solid tumors

Antibody 253
article thumbnail

Amgen pays $900M for Teneobio and bets bigger on next-gen antibody drugs

Bio Pharma Dive

The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech

Antibody 241
article thumbnail

Disc and Mabwell sign deal for licence to antibodies portfolio

Pharmaceutical Technology

Disc Medicine has entered an exclusive licence agreement with Mabwell Therapeutics for the latter’s new Anti-TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) monoclonal antibodies to modulate iron homeostasis.

Antibody 130
article thumbnail

Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Scienmag

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM).

article thumbnail

How a COVID-19 infection spurs antibodies against common colds

Scienmag

LA JOLLA, CA—Getting sick with a common cold doesn’t make you immune to COVID-19, but a COVID-19 infection might, at least temporarily, boost the number of antibodies you have against common cold-causing coronaviruses and the SARS-CoV-1 and MERS-CoV viruses, all of which are closely related.

article thumbnail

AstraZeneca antibody cleared by FDA for preventive use against COVID-19

Bio Pharma Dive

Evusheld, a combination of two antibodies, is meant to be long-acting, proving protective against disease through six months in clinical testing

Antibody 158
article thumbnail

US buys up supply of new Lilly antibody meant to work versus omicron

Bio Pharma Dive

Distribution of Lilly's earlier antibody treatments was halted as testing showed them ineffective against omicron. Bebtelovimab appears able to neutralize the variant, and was authorized by the FDA on Friday

Antibody 223
article thumbnail

Merck to pay almost $3B for VelosBio, broadening antibody cancer drug push

Bio Pharma Dive

Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround

Antibody 267
article thumbnail

US pauses distribution of Regeneron, Lilly antibodies over omicron concerns

Bio Pharma Dive

The decision follows worrisome results in lab studies that indicated omicron can evade both drugs and leaves the U.S. with fewer treatments to respond to the variant's spread

Antibody 274
article thumbnail

Scientists analyze structure of antibodies that could be key to more effective cancer treatments

Scienmag

Researchers at the University of Southampton have gained unprecedented new insight into the key properties of an antibody needed to fight off cancer. The findings have enabled the Southampton team to design antibodies to […].

article thumbnail

Scripps Research scientists explain what makes COVID-19 antibody “J08” so potent

Scienmag

LA JOLLA, CA—Last year, scientists at Scripps Research and Toscana Life Sciences studied the blood of 14 COVID-19 survivors to find the most potent antibodies against the SARS-CoV-2 virus. Medicine & Health antibody COVID19 explain J08 potent research scientists Scripps

article thumbnail

Antibody with engineered peptide targets bone metastasis

Scienmag

Cancer antibody bone Engineered metastasis peptide targetsHOUSTON – (Jan. 24, 2022) – A moderate amount of a peptide-enhanced, biological cancer drug goes a long way in treating breast cancers that metastasize to the bone.

article thumbnail

Sanofi pays IGM $150M, continuing search for better antibody drugs

Bio Pharma Dive

The French pharmaceutical giant has inked its third antibody-focused deal since December, this time betting on a Californian biotech trying to pioneer a new class of medicines

Antibody 130
article thumbnail

Biocytogen and ADC to evaluate antibodies for three cancer targets

Pharmaceutical Technology

Biocytogen Pharmaceuticals and ADC Therapeutics have signed an assessment and option agreement for evaluating antibodies against three tumour targets. Under the deal, ADC Therapeutics will receive a licence from Biocytogen to evaluate the latter’s antibodies against the targets.

Antibody 130
article thumbnail

Monoclonal antibodies challenge marketed small-molecule Alzheimer’s dominance

Pharmaceutical Technology

The three leading Alzheimer’s disease (AD) drugs currently in development are all monoclonal antibodies—donanemab by Eli Lilly , lecanemab by Eisai and Biogen , and gantenerumab by Roche. Monoclonal antibodies make up half of these, with an 11% share of all AD approvals.

Antibody 141
article thumbnail

New antibody detection method for coronavirus that does not require a blood sample

Scienmag

Now, investigators from Japan have developed a new antibody-based method for the rapid and reliable detection of SARS-CoV-2 […]. Medicine & Health antibody blood coronavirus detection method require sample

article thumbnail

Syncromune and Eucure enter antibody licence deal

Pharmaceutical Technology

Syncromune and Biocytogen Pharmaceuticals’ wholly owned subsidiary Eucure Biopharma have entered an exclusive global licence agreement for OX40 antibody YH002 and two other active ingredients. .

Antibody 130
article thumbnail

New COVID-19 nasal spray outperforms current antibody treatments in mice

Scienmag

Medicine & Health antibody COVID19 current mice nasal outperforms spray treatmentsA new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St.

article thumbnail

Valneva and Pfizer report Lyme disease antibody data

Pharma Times

Children and adults have been treated using the Lyme disease antibody candidate VLA15

article thumbnail

JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business

Bio Pharma Dive

Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction.

Antibody 244
article thumbnail

Twist and Ildong to develop antibodies for immuno-oncology applications

Pharmaceutical Technology

Ildong Pharmaceutical will licence a suite of Twist Bioscience's VHH antibody libraries after the two companies entered a partnership agreement. Antibodies comprise two variable domains, heavy and light chains.

Antibody 141
article thumbnail

Regeneron enlists Roche to boost production of COVID-19 antibody drug

Bio Pharma Dive

Together, the companies expect to make three and a half times as many doses of Regeneron's antibody drug than the U.S. biotech could on its own

Antibody 173
article thumbnail

In multiple myeloma, cell therapies lead but antibody drugs could follow fast

Bio Pharma Dive

But a growing group of antibody drugs, several of which were showcased at ASH, aren't far behind Two cell therapies might soon be approved for the blood cancer.

Antibody 241
article thumbnail

Mayo Clinic researchers develop new antibody test to diagnose MS

Scienmag

Mayo Clinic researchers have validated a new antibody test to diagnose multiple sclerosis (MS), a potentially disabling disease of the brain and spinal cord. An antibody typically consists of two immunoglobulin heavy chains and […]. Latest News antibody Clinic develop diagnose Mayo researchers testROCHESTER, Minn. Nearly 1 million people in the U.S. are affected by MS, according to the National Multiple Sclerosis Society.